Developer docs
API playgroundTry for free, no card

Search company profiles

Sonrai Analytics

Full company profile

uuid00003w7

Namestring
Sonrai Analytics
Legal namestring
Sonrai Analytics
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Sonrai Analytics is a Belfast-based precision medicine analytics company founded in 2018 by Dr Darragh McArt and Dr Deva Senevirathne. It operates an AI-powered multi-modal data analytics platform called Sonrai Discovery that integrates genomic, proteomic, imaging, and clinical data inside a secure Trusted Research Environment (TRE). The platform uses machine learning techniques including XGBoost, t-SNE, MOFA, and UMAP for dimensionality reduction, clustering, and classification, with published performance of 94% sensitivity, 89% specificity, and AUC-ROC of 0.93 on early cancer detection models built with AWS SageMaker.

The company delivers its capabilities through three decision modules — Translational Analytics, Target ID & Validation, and Patient Stratification — that span the drug development lifecycle from preclinical research through clinical trials. Its primary customers are pharmaceutical and biotech companies including Roche, Candel Therapeutics, AOA Dx, and Plectonic Biotech, alongside institutional users such as NHS and Cancer Research UK.

Sonrai monetizes through a combination of platform subscriptions and professional services in which its scientists work alongside client R&D teams to analyze datasets and produce decision-ready translational evidence. Go-to-market is enterprise field sales with consultative 'Book Demo' CTAs, supplemented by a flagship global strategic partnership with SmartLabs (announced August 2025) that provides distribution into SmartLabs' network of five managed research centers. The company has raised approximately £2.175M in seed-plus funding plus undisclosed rounds from Eckuity (2022) and Beach Equity (2025), and operates from Belfast with expansion into US and EU markets.

Short descriptiontext

Sonrai Analytics is a Belfast-based precision medicine company that uses its Sonrai Discovery platform to integrate multi-modal biomedical data with AI/ML workflows inside a secure Trusted Research Environment, serving pharmaceutical and biotech clients including Roche, Candel Therapeutics, and NHS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine analytics, biomarker discovery platform, multi-omics data analysis, clinical trial analytics, translational research software
Industry4 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Processing & Data Preparation7374
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Medicine Analytics Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Analytics Platform and Services
TypeSubscription Recurring
Description

AI-powered data analytics platform and scientific analysis services for pharma and biotech companies to discover biomarkers, stratify patients, and support clinical trial decisions

sonraianalytics.com
2Professional Services
TypeProfessional Services
Description

Scientific expertise and consulting services where Sonrai scientists work alongside client R&D teams to analyze datasets and deliver translational evidence

sonraianalytics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Sonrai Discovery
Description

AI-powered analytics platform for precision medicine biomarker discovery, data integration, and analysis within a secure, governed research environment.

sonraianalytics.com
Core offering1 text field

Sonrai Analytics operates Sonrai Discovery, a cloud-native AI-powered analytics platform that integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure Trusted Research Environment (TRE) to enable biomarker discovery, patient stratification, and translational analysis for precision medicine teams. The company combines the platform with scientific services where Sonrai scientists work alongside client R&D teams to deliver decision-ready evidence from complex biomedical datasets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 94% sensitivity, 89% specificity, AUC-ROC of 0.93 for early cancer detection models
+8 more records
Product overview1 text field

Sonrai Analytics offers a unified AI-powered precision medicine analytics platform called Sonrai Discovery, which is supplemented by three core decision modules: Translational Analytics, Target ID & Validation, and Patient Stratification. The platform integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure, governed Trusted Research Environment to generate decision-ready evidence for biomarker discovery, patient stratification, and drug development programs.

Product and service2 records
1Sonrai Discovery Platform
CategoryPrecision Medicine Analytics Software
Description

Cloud-native AI analytics platform that serves as the foundation for all Sonrai services. Provides a secure Trusted Research Environment (TRE) with reproducible workflows, multi-modal data integration (genomic, proteomic, imaging, clinical), and AI-assisted exploration capabilities for biomarker discovery, patient stratification, and translational analysis. Designed for pharmaceutical, biotechnology, and translational research organizations.

2Multi-Omics Data Analysis Services
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-03
Description

SmartLabs partnered with Sonrai to integrate AI analytics into its network of research centers. The collaboration aims to accelerate biomarker discovery and diagnostic workflows for biotech and pharmaceutical companies by offering Sonrai's AI platform Sonrai Discovery.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-28
Description

SmartLabs and Sonrai Analytics announced a global strategic partnership to integrate Sonrai's AI analytics platform Sonrai Discovery into SmartLabs' network of five managed research centers, exclusively available to SmartLabs' member companies. Both companies will jointly develop bespoke AI applications and laboratory informatics tools combining experimental and infrastructure data to predict scientific outcomes and accelerate discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Sonrai and Plectonic Biotech joined forces to advance precision immunotherapies for cancer through combined AI analytics and immunotherapy development expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

UK-based AI and data analytics firm Sonrai partnered with US biotechnology company AOA Dx to develop a serum-based multi-omic liquid biopsy test for early ovarian cancer detection. The partnership combines artificial intelligence with multi-omics approaches to improve diagnostic accuracy and patient outcomes.

5AWS (Amazon Web Services)
Strategic tierCoreTypeTechnology or Integration
Description

Sonrai partnered with AWS to build an MLOps framework using Amazon SageMaker AI for precision medicine biomarker discovery. The solution processed over 8,000 potential biomarkers across proteomics, metabolomics, and lipidomics modalities, generating 15 models with top performer achieving 94% sensitivity, 89% specificity, and AUC-ROC of 0.93 for early cancer detection.

aws.amazon.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Recursion combines high-throughput wet-lab biology with AI-driven phenomics and multi-omic analysis to identify targets and biomarkers, operating in adjacent territory to Sonrai's target ID and biomarker discovery work.

TypeDirect peer
Description

Owkin applies federated AI to multi-omic and imaging data for pharma R&D and clinical trials, directly overlapping Sonrai's biomarker discovery, patient stratification, and translational analysis use cases for biopharma.

3Tempus Labs
TypeBroad incumbent
Description

Tempus is a large-scale precision medicine platform combining multi-omic sequencing, imaging AI, and a TRE-style research environment for pharma, targeting the same biopharma buyers as Sonrai but with much broader data assets and capital base.

TypeDirect peer
Description

Insitro builds AI/ML models on multi-modal biological data (genomics, imaging, clinical) to accelerate drug discovery, mirroring Sonrai's data integration and predictive modeling approach for pharma pipelines.

TypeBroad incumbent
Description

Schrödinger provides computational biology and physics-based modeling software widely adopted in pharma R&D, overlapping with Sonrai's decision modules for target prioritization and translational evidence generation.

TypeBroad incumbent
Description

Exscientia applies AI-driven precision medicine, including patient stratification and biomarker-guided clinical trials for pharma partners, closely tracking Sonrai's translational analytics and patient stratification modules.

TypeDirect peer
Description

BenevolentAI uses AI on multi-modal biomedical data to discover targets and biomarkers for pharma R&D, comparable to Sonrai's target ID/validation and biomarker discovery offerings.

TypeDirect peer
Description

PathAI applies AI to digital pathology and integrates pathology findings with molecular/clinical data for biomarker discovery, directly comparable to Sonrai's H&E/IHC imaging AI and multimodal analytics capabilities.

9Aignostics
TypeEmerging player
Description

Aignostics is an emerging AI digital pathology platform serving pharma biomarker programs, overlapping with Sonrai's computational pathology and multimodal biomarker discovery workflows.

TypeBroad incumbent
Description

Ginkgo Bioworks provides large-scale biological engineering and multi-omic data infrastructure used by pharma and biotech, addressing adjacent target ID, biomarker discovery, and synthetic biology analytics needs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sonrai Analytics

Precision Medicine Analytics Softwaresonraianalytics.com

Sonrai Analytics is a Belfast-based precision medicine company that uses its Sonrai Discovery platform to integrate multi-modal biomedical data with AI/ML workflows inside a secure Trusted Research Environment, serving pharmaceutical and biotech clients including Roche, Candel Therapeutics, and NHS.

What Sonrai Analytics does

Sonrai Analytics is a Belfast-based precision medicine analytics company founded in 2018 by Dr Darragh McArt and Dr Deva Senevirathne. It operates an AI-powered multi-modal data analytics platform called Sonrai Discovery that integrates genomic, proteomic, imaging, and clinical data inside a secure Trusted Research Environment (TRE). The platform uses machine learning techniques including XGBoost, t-SNE, MOFA, and UMAP for dimensionality reduction, clustering, and classification, with published performance of 94% sensitivity, 89% specificity, and AUC-ROC of 0.93 on early cancer detection models built with AWS SageMaker.

The company delivers its capabilities through three decision modules — Translational Analytics, Target ID & Validation, and Patient Stratification — that span the drug development lifecycle from preclinical research through clinical trials. Its primary customers are pharmaceutical and biotech companies including Roche, Candel Therapeutics, AOA Dx, and Plectonic Biotech, alongside institutional users such as NHS and Cancer Research UK.

Sonrai monetizes through a combination of platform subscriptions and professional services in which its scientists work alongside client R&D teams to analyze datasets and produce decision-ready translational evidence. Go-to-market is enterprise field sales with consultative 'Book Demo' CTAs, supplemented by a flagship global strategic partnership with SmartLabs (announced August 2025) that provides distribution into SmartLabs' network of five managed research centers. The company has raised approximately £2.175M in seed-plus funding plus undisclosed rounds from Eckuity (2022) and Beach Equity (2025), and operates from Belfast with expansion into US and EU markets.

Sonrai Analytics firmographics

Firmographics
Name
Sonrai Analytics
Legal name
Sonrai Analytics
Website
https://sonraianalytics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Sonrai Analytics is a Belfast-based precision medicine company that uses its Sonrai Discovery platform to integrate multi-modal biomedical data with AI/ML workflows inside a secure Trusted Research Environment, serving pharmaceutical and biotech clients including Roche, Candel Therapeutics, and NHS.
Ownership category
akta.pro rank

Sonrai Analytics industry classification

Industry
Product category
Precision Medicine Analytics Software
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Processing & Data Preparation (7374), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Precision medicine analytics
  • Biomarker discovery platform
  • Multi-omics data analysis
  • Clinical trial analytics
  • Translational research software

Where Sonrai Analytics is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Sonrai Analytics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Analytics Platform and Services: AI-powered data analytics platform and scientific analysis services for pharma and biotech companies to discover biomarkers, stratify patients, and support clinical trial decisions
  2. Professional Services: Scientific expertise and consulting services where Sonrai scientists work alongside client R&D teams to analyze datasets and deliver translational evidence

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Sonrai Analytics product offering

Product offering

Core offering

Sonrai Analytics operates Sonrai Discovery, a cloud-native AI-powered analytics platform that integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure Trusted Research Environment (TRE) to enable biomarker discovery, patient stratification, and translational analysis for precision medicine teams. The company combines the platform with scientific services where Sonrai scientists work alongside client R&D teams to deliver decision-ready evidence from complex biomedical datasets.

Product overview

Sonrai Analytics offers a unified AI-powered precision medicine analytics platform called Sonrai Discovery, which is supplemented by three core decision modules: Translational Analytics, Target ID & Validation, and Patient Stratification. The platform integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure, governed Trusted Research Environment to generate decision-ready evidence for biomarker discovery, patient stratification, and drug development programs.

Differentiator

Problem solved

Functional benefit

Brands

  • Sonrai Discovery: AI-powered analytics platform for precision medicine biomarker discovery, data integration, and analysis within a secure, governed research environment.

Products and services

  • Sonrai Discovery Platform Cloud-native AI analytics platform that serves as the foundation for all Sonrai services. Provides a secure Trusted Research Environment (TRE) with reproducible workflows, multi-modal data integration (genomic, proteomic, imaging, clinical), and AI-assisted exploration capabilities for biomarker discovery, patient stratification, and translational analysis. Designed for pharmaceutical, biotechnology, and translational research organizations.
  • Multi-Omics Data Analysis Services

Quantifiable outcome

  • 94% sensitivity, 89% specificity, AUC-ROC of 0.93 for early cancer detection models
  • +8 more outcomes

Companies that use Sonrai Analytics

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Sonrai Analytics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Sonrai Analytics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • SmartLabscoreTechnology or Integration · 3 September 2025SmartLabs partnered with Sonrai to integrate AI analytics into its network of research centers. The collaboration aims to accelerate biomarker discovery and diagnostic workflows for biotech and pharmaceutical companies by offering Sonrai's AI platform Sonrai Discovery.
  • SmartLabsflagshipStrategic or Co-development Partner · 28 August 2025SmartLabs and Sonrai Analytics announced a global strategic partnership to integrate Sonrai's AI analytics platform Sonrai Discovery into SmartLabs' network of five managed research centers, exclusively available to SmartLabs' member companies. Both companies will jointly develop bespoke AI applications and laboratory informatics tools combining experimental and infrastructure data to predict scientific outcomes and accelerate discovery.
  • Plectonic BiotechcoreStrategic or Co-development Partner · 23 June 2025Sonrai and Plectonic Biotech joined forces to advance precision immunotherapies for cancer through combined AI analytics and immunotherapy development expertise.
  • AOA DxcoreStrategic or Co-development Partner · 1 May 2025UK-based AI and data analytics firm Sonrai partnered with US biotechnology company AOA Dx to develop a serum-based multi-omic liquid biopsy test for early ovarian cancer detection. The partnership combines artificial intelligence with multi-omics approaches to improve diagnostic accuracy and patient outcomes.
  • AWS (Amazon Web Services)coreTechnology or IntegrationSonrai partnered with AWS to build an MLOps framework using Amazon SageMaker AI for precision medicine biomarker discovery. The solution processed over 8,000 potential biomarkers across proteomics, metabolomics, and lipidomics modalities, generating 15 models with top performer achieving 94% sensitivity, 89% specificity, and AUC-ROC of 0.93 for early cancer detection.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Sonrai Analytics competitors and assessment

Company assessment

Broad incumbents

  • Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab biology with AI-driven phenomics and multi-omic analysis to identify targets and biomarkers, operating in adjacent territory to Sonrai's target ID and biomarker discovery work.
  • Tempus Labs: Tempus is a large-scale precision medicine platform combining multi-omic sequencing, imaging AI, and a TRE-style research environment for pharma, targeting the same biopharma buyers as Sonrai but with much broader data assets and capital base.
  • Schrödinger: Schrödinger provides computational biology and physics-based modeling software widely adopted in pharma R&D, overlapping with Sonrai's decision modules for target prioritization and translational evidence generation.
  • Exscientia: Exscientia applies AI-driven precision medicine, including patient stratification and biomarker-guided clinical trials for pharma partners, closely tracking Sonrai's translational analytics and patient stratification modules.
  • Ginkgo Bioworks: Ginkgo Bioworks provides large-scale biological engineering and multi-omic data infrastructure used by pharma and biotech, addressing adjacent target ID, biomarker discovery, and synthetic biology analytics needs.

Direct peers

  • Owkin: Owkin applies federated AI to multi-omic and imaging data for pharma R&D and clinical trials, directly overlapping Sonrai's biomarker discovery, patient stratification, and translational analysis use cases for biopharma.
  • Insitro: Insitro builds AI/ML models on multi-modal biological data (genomics, imaging, clinical) to accelerate drug discovery, mirroring Sonrai's data integration and predictive modeling approach for pharma pipelines.
  • BenevolentAI: BenevolentAI uses AI on multi-modal biomedical data to discover targets and biomarkers for pharma R&D, comparable to Sonrai's target ID/validation and biomarker discovery offerings.
  • PathAI: PathAI applies AI to digital pathology and integrates pathology findings with molecular/clinical data for biomarker discovery, directly comparable to Sonrai's H&E/IHC imaging AI and multimodal analytics capabilities.

Emerging players

  • Aignostics: Aignostics is an emerging AI digital pathology platform serving pharma biomarker programs, overlapping with Sonrai's computational pathology and multimodal biomarker discovery workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Sonrai Analytics social profiles

Digital presence

Sonrai Analytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sonrai Analytics leadership team

Management profile

Number of profiles

Profiles8 records

Sonrai Analytics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sonrai Analytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sonrai Analytics

What does Sonrai Analytics do?

Sonrai Analytics operates Sonrai Discovery, a cloud-native AI-powered analytics platform that integrates multi-modal biomedical data (genomic, proteomic, imaging, and clinical) within a secure Trusted Research Environment (TRE) to enable biomarker discovery, patient stratification, and translational analysis for precision medicine teams. The company combines the platform with scientific services where Sonrai scientists work alongside client R&D teams to deliver decision-ready evidence from complex biomedical datasets.

Is Sonrai Analytics a public or private company?

Sonrai Analytics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sonrai Analytics founded?

Sonrai Analytics was founded in 2018. It employs 11 to 50 people.

Where is Sonrai Analytics based?

Sonrai Analytics is headquartered in Belfast, United Kingdom, in the Europe region.

How does Sonrai Analytics make money?

Two revenue lines are on record. Analytics Platform and Services are the primary driver. The others are professional Services.

Who are Sonrai Analytics's main competitors?

Broad incumbents on record are Recursion Pharmaceuticals, Tempus Labs, Schrödinger, Exscientia and Ginkgo Bioworks. Direct peers are Owkin, Insitro, BenevolentAI and PathAI. Aignostics is listed as an emerging player.

Does Sonrai Analytics have an API?

No public API is recorded for Sonrai Analytics.

What industry is Sonrai Analytics in?

Sonrai Analytics's product category is Precision Medicine Analytics Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Trend Insights: The Impact of Recent Advancements on the Ovarian Cancer Diagnostics MarketThe ovarian cancer diagnostics market is projected to grow to $4.2 billion by 2030, expanding at a compound annual growth rate of 7.7%, driven by AI-driven diagnostic technologies, precision oncology funding, and biomarker-based testing. In May 2025, UK-based AI and data analytics firm Sonrai partnered with US biotechnology company AOA Dx to develop a serum-based multi-omic liquid biopsy test for early ovarian cancer detection, combining artificial intelligence with multi-omics approaches to improve diagnostic accuracy and patient outcomes.Clinical Lab ProductsSmartLabs Partners with Sonrai to Integrate AI Analytics PlatformSmartLabs has partnered with Sonrai to integrate AI analytics into its network of research centers. The collaboration aims to accelerate biomarker discovery and diagnostic workflows for biotech and pharmaceutical companies by offering Sonrai's AI platform, Sonrai Discovery.PR NewswireSmartLabs et Sonrai lancent un partenariat exclusif pour offrir des capacités d'IA avancées aux sociétés membres de SmartLabsSmartLabs and Sonrai Analytics announced a global strategic partnership on August 28, 2025, integrating Sonrai's AI-powered data management platform, Sonrai Discovery, into SmartLabs' network of five advanced research centers. SmartLabs will offer Sonrai's analytics platform to its member companies and the two firms will jointly develop exclusive AI and laboratory computing applications designed to accelerate scientific discovery and biomarker identification. The partnership represents SmartLabs' expansion into AI-driven research solutions to meet growing demand from biotech and pharmaceutical companies for advanced data analytics capabilities.SonraianalyticsSonrai Case StudiesSonrai Systems presents a collection of case studies demonstrating the efficiency gains achieved by pharmaceutical and diagnostic clients using its AI-driven discovery platform. The content highlights specific metrics, such as Candel Therapeutics achieving 93% faster biomarker identification and significant reductions in clinical trial timelines and costs for various unnamed partners. These examples illustrate the company's role in accelerating drug development processes through multi-modal data integration and cloud-based analytics.DrugPatentWatchAI in Action: Accelerating the Drug Discovery PipelineA DrugPatentWatch blog post argues that AI can overhaul drug discovery by shifting from hypothesis-driven, one-target-at-a-time research to data-driven, systems-level approaches. It cites a Sonrai Analytics case cutting target identification from 12 to 5 months and validation from 25 to 11 months, plus Insilico Medicine's 18-month path to Rentosertib.DrugPatentWatchAI in Action: Accelerating the Drug Discovery PipelineA DrugPatentWatch blog post argues that AI can overhaul drug discovery by shifting from hypothesis-driven, one-target-at-a-time research to data-driven, systems-level approaches. It cites a 12- to 15-year development timeline, $2.6-2.8 billion average costs, and a 7.9% Phase I-to-market success rate, with Phase II failure at 28.9%. It highlights Sonrai Analytics' 21-month acceleration and Insilico Medicine's 18-month Rentosertib program.Cancer Research HorizonsSonrai Analytics and Cancer Research Horizons join forces to drive precision medicine innovationSonrai Analytics and Cancer Research Horizons, the innovation arm of Cancer Research UK, have announced a partnership in which Cancer Research Horizons will use Sonrai's AI-enabled discovery platform, Sonrai Discovery, to accelerate biomarker discovery across its funded UK cancer programmes. Selected universities and spin-out companies will receive onboarding and training, including dataset upload and reporting support. Financial terms were not disclosed.Silicon RepublicSonrai Analytics is taking its AI cancer detection tech to the UAESonrai Analytics partnered with UAE-based Alliance Care Technologies to deploy its AI technology for cancer detection and biomarker discovery in the region. The collaboration aims to assist clinicians in accelerated tumour detection and improve patient outcomes. Sonrai raised £700,000 in seed funding in March 2020 and £2m last year.SonraianalyticsSonrai Analytics Secures US Investment from EckuityHealthTech venture firm Eckuity has invested in Sonrai Analytics, a Northern Irish artificial intelligence company specializing in biomarker discovery for biotech and pharma organizations. This investment supports Sonrai's commercial expansion into the US market and its goal to accelerate the development of treatments through AI-driven data analytics.